Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY ...

All told, the S&P 500 slipped 7.20 points to 5,738.17, but it still closed out a third straight winning week and its sixth in ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

This health news roundup covers significant advances and alerts, including the approval of Bristol Myers' new schizophrenia ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

U.S. stocks close a record-setting week with mixed results, as hope builds for the economy to manage high inflation without ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

(Reuters) -The blue-chip Dow Jones Industrial Average closed at a record high on Friday as investors welcomed a subdued ...